(+)-JQ1

Catalog No.S7110

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Size Price Stock Quantity  
USD 270 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

8 Customer Reviews

  • The BET protein inhibitor JQ1 reduces c-Myc expression and attenuates primary MCC cell proliferation. A, decreased c-Myc expression in MCC-3 and MCC-5 treated with JQ1 (800 nmol/L) for 72 hours by qRT-PCR and immunoblotting. The mRNA expression of target genes was normalized to that of MRPS2 and a value of 1.0 was assigned to the mRNA expression of target genes in the control group (means+SEM; **, P < 0.01 vs. control); b-actin was used as a loading control for immunoblotting.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

    Immunohistochemical staining of xenograft tumor tissues. Immunohistochemical staining of xenograft tumor tissues with the indicated antibodies. p21-, p27-, p57-, and Ki67 positive cells (brown staining) were quantified at x400 magnification (meansSEM;**, P < 0.01;***, P < 0.001 vs. control); scale bars, 10 um.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

  • (D) Effect of JQ1 on alterations of actin cytoskeleton in VEGF-induced HUVECs. The cells were pretreated with DMSO or JQ1 (100 nM) for 6 h, and stimulated with VEGF (10 ng/mL) for 12 h. F-actin (red) and nuclei (blue) were stained with phalloidin and DAPI, respectively. Representative images from 3 independent experiments.

    Sci Rep, 2016, 6:23770.. (+)-JQ1 purchased from Selleck.

    Sensitivity of BEZ235-resistant cells to JQ-1 using the MTT assay.

    Oncotarget, 2016, 6(7):5134-46.. (+)-JQ1 purchased from Selleck.

  • B. Repressed MCC-3 xenograft tumor growth upon combined treatment with MLN0128 and JQ1. Tumor bearing mice were treated with MLN0128 or vehicle at 1 mg/kg/day by oral gavage and JQ1 or vehicle at 50 mg/kg/day by i.p. injection for a period of 30 days. C. A more effective reduction of MCC-3 xenograft tumor growth in the group treated with combined therapy. Fold-reduction of tumor growth was calculated as average tumor growth of control group divided by average tumor growth of treatment group. Tumor growth was calculated as final average tumor volume minus initial average tumor volume in each group.

    Oncotarget, 2016, 7(6):6576-92.. (+)-JQ1 purchased from Selleck.

    JQ1 induces cell cycle arrest and apoptosis in Cal27 cells. (C) Cal27 cells were treated with JQ1 for 24 h and whole cell lysates were tested by western blot assays for the expression of cleaved-caspase-3. GAPDH was used as a loading control. (D) Apoptosis of Cal27 cells treated with JQ1 at 0 and 0.5 µM JQ1; *P<0.05 vs. control (the DMSO group)

    Oncol Rep, 2016, 36(4):1989-96.. (+)-JQ1 purchased from Selleck.

  • immunofluorescence staining of BRD4 in ACC-LM and ACC-83 cells treated with JQ1 at the concentration of 1 µM for 24 h (×200).

    Biol Res, 2017, 50(1):19. (+)-JQ1 purchased from Selleck.

    Effect of BET domain family inhibition on AMI damage in cardiomyocytes. (A) LDH and (B) CK-MB activity in the serum. #P<0.01 vs. sham group; @P<0.05 and &P<0.01 vs. AMI group. BET, bromodomain and extra-terminal; AMI, acute myocardial infarction; LDH, lactate dehydrogenase; CK-MB, creatine kinase MB isoenzyme.

    Exp Ther Med, 2015, 10(6):2319-2324.. (+)-JQ1 purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  M3\MTGNmdGxiVnnhZoltcXS7IFHzd4F6 MYOyOVAwPTByL{GwNFAhdk1? MlrtNlQwPDhxN{KgbC=> MUTEUXNQ NX7kco11cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S1iZHXw[Y5l\W62IH3hco5meg>? MkXTNlY4ODd6OEG=
BCPAP MknDR4VtdCCYaXHibYxqfHliQYPzZZk> MljqNlUxNzVyMD:xNFAxKG6P NFewOHMzPC92OD:3NkBp Mk\2SG1UVw>? Mn\lbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> M1rFelI3PzB5OEix
K1  MnrKR4VtdCCFeXPs[UBCe3OjeR?= NXrjVIRYOjVyL{WwNE8yODByIH7N NGP0O|k4OiCq MUDEUXNQ MoTpZZJz\XO2czDj[YxtKGO7Y3zlJIF1KEdyL1exJJBp[XOn NHOydW0zPjdyN{i4NS=>
BCPAP MXLD[YxtKEO7Y3zlJGF{e2G7 NGTPbYYzPTBxNUCwM|ExODBibl2= NUDj[WFMPzJiaB?= NX\HPFRTTE2VTx?= MUXhdpJme3S|IHPlcIwh[3mlbHWgZZQhTzBxR{GgdIhie2V? NX7x[WlZOjZ5MEe4PFE>
Hep3B NGnpV2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHMeXYxNTFyIN88US=> MlzoOUBl NXvSN|htTE2VTx?= NInNS5VKSzVyPUCuNFgh|ryP NXW0XHRWOjZ3N{WxOlc>
HCCLM3 MonIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2GwW|AuOTBizszN MlvuOUBl MUPEUXNQ MXHJR|UxRTBwMUSg{txO M1SxSFI3PTd3MU[3
HuH7 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HqRlAuOTBizszN MXu1JIQ> MkLuSG1UVw>? NEPzWYxKSzVyPUCuNlEh|ryP NF;r[44zPjV5NUG2Oy=>
HepG2 M1e4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHVNE0yOCEQvF2= MVO1JIQ> NXLrXJczTE2VTx?= NFi4TFNKSzVyPUCuN|Qh|ryP NYTi[5N3OjZ3N{WxOlc>
SMMC7721 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDSbFcxNTFyIN88US=> NHX1fIk2KGR? MkjwSG1UVw>? NV;iXVBSUUN3ME2wMlQyKM7:TR?= MVWyOlU4PTF4Nx?=
BEL7402 M3T3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvrNHIxNTFyIN88US=> MonsOUBl MkPsSG1UVw>? MnPXTWM2OD1yLkS3JO69VQ>? MYKyOlU4PTF4Nx?=
MHCC97H NXy3ZWVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYWwMVExKM7:TR?= NV;3SmR4PSCm M3TiOGROW09? M1vGd2lEPTB;MD60NUDPxE1? NXnDUoFvOjZ3N{WxOlc>
Hep3B MXrD[YxtKEO7Y3zlJGF{e2G7 MoTDNE4yNzBwNT:yMlUh|ryP MX60PEBp NFPMb3ZFVVOR NYTnToh2dGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZiSFPDJINmdGy|IHnuJJN2[i2JMTDwbIF{\cLi NYLHb4dMOjZ3N{WxOlc>
HCCLM3 Mmq3R4VtdCCFeXPs[UBCe3OjeR?= NIfSTocxNjFxMD61M|IvPSEQvF2= NEX0NYQ1QCCq NG\jO|dFVVOR MnPjcIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhUEOFIHPlcIx{KGmwIIP1Zk1IOSCyaHHz[eKh NFe3XXozPjV5NUG2Oy=>
Hep3B MojaRZBweHSxc3nzJGF{e2G7 M3\3eFAvOS9yLkWvNk42KM7:TR?= M1\vSlQ5KGh? MYXEUXNQ NI\wWnhi[3SrdnH0[ZMh[2G|cHHz[U0{KGGwZDDjZZNx[XOnLUmg[ZhxemW|c3nvckBidmRiaX7keYNm\CCSQWLQJINt\WG4YXflJIF{KHenbHygZZMh[3m2b3Podo9u\SClIILlcIVie2ViaX70c{B1cGViY4n0c5Bt[XOvIH\yc40hdWm2b3Poc45lemmj NHPHRW0zPjV5NUG2Oy=>
HCCLM3 NVza[mxVSXCxcITvd4l{KEG|c3H5 NFHqdWgxNjFxMD61M|IvPSEQvF2= MVy0PEBp NIC2WHlFVVOR MnLBZYN1cX[jdHXzJINie3Cjc3WtN{BidmRiY3HzdIF{\S17IHX4dJJme3Orb36gZY5lKGmwZIXj[YQhWEGUUDDjcIVifmGpZTDhd{B4\WyuIHHzJIN6fG:laILvcYUh[yC{ZXzlZZNmKGmwdH:geIhmKGO7dH;wcIF{dSCocn;tJI1qfG:laH;u[JJq[Q>? M{j6U|I3PTd3MU[3
A549 M2CxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUCwMlEuOTBizszN M{G3dVczKGh? NGnod5RqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M4DrOFI3PDF3MkK1
H157 NW\Ye41nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[wMlEuOTBizszN MX[3NkBp MnXFbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NWXkfZRYOjZ2MUWyNlU>
H1299 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\5NE4yNTFyIN88US=> NHLPcJM4OiCq M4LzZYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1LMPVI3PDF3MkK1
A549 NV7ac5hiTnWwY4Tpc44hSXO|YYm= MmjaNU8zNjVxNTFOwG0> MVKxNkBp MoO4xsB4\WGtbImg[IVkemWjc3XkJGJkdC1{IHzleoVtew>? MVyyOlQyPTJ{NR?=
H1299 NHq4RodHfW6ldHnvckBCe3OjeR?= NXTLU3JYOS9{LkWvOUDPxE1? M2PTSFEzKGh? NWfh[5ZKyqC5ZXHrcJkh\GWlcnXhd4VlKEKlbD2yJIxmfmWucx?= NH;O[JMzPjRzNUKyOS=>
H157 MYLGeY5kfGmxbjDBd5NigQ>? M3;CeFEwOi53L{Wg{txO NEDlOlMyOiCq MoPr[IVkemWjc3XkJGRTPCCneIDy[ZN{cW:w NWHHTpBvOjZ2MUWyNlU>
H1299 NYDDNHNFTnWwY4Tpc44hSXO|YYm= M1S5V|EwOi53L{Wg{txO MUKxNkBp NGj2O2tl\WO{ZXHz[YQhTFJ2IHX4dJJme3Orb36= MXSyOlQyPTJ{NR?=
C8161 Ml3WR4VtdCCYaXHibYxqfHliQYPzZZk> M4ntVlAuOiEQvF2= NYrJ[pRFPCCm Mn7uSG1UVw>? MX7k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYPFfGhGOjZ|OUeyNlM>
Mel285 NGjSTY9E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYjQV|JHOC1{IN88US=> NUKwOXJMPCCm NG\YT21FVVOR NEHUPGZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NIjqR5UzPjN7N{KyNy=>
Mel290 NV\WVVBpS2WubDDWbYFjcWyrdImgRZN{[Xl? NUPkPYFWOC1{IN88US=> NVixcXNmPCCm MnG5SG1UVw>? NYrNRm02\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NULoZpIyOjZ|OUeyNlM>
92.1 NF\hWGdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NEi1TpoxNTJizszN M2rqXFQh\A>? MkDFSG1UVw>? MWrk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mm\FNlY{QTd{MkO=
Omm1.3 M2jhZ2NmdGxiVnnhZoltcXS7IFHzd4F6 MYewMVIh|ryP NGfKOVQ1KGR? NVPQPXg4TE2VTx?= M2PJfIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHW3XoczPjN7N{KyNy=>
Mel202 MVnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NF70[owxNTJizszN Mmm0OEBl MXTEUXNQ MkCx[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NGrqW4YzPjN7N{KyNy=>
Mel270 NXHqeYtnS2WubDDWbYFjcWyrdImgRZN{[Xl? MYmwMVIh|ryP Mn\KOEBl NHjibIdFVVOR NVi1d4pC\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MUmyOlM6PzJ{Mx?=
Omm1 MoOxR4VtdCCYaXHibYxqfHliQYPzZZk> NGXBUnUxNTJizszN MVG0JIQ> M365XWROW09? MmLj[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MojsNlY{QTd{MkO=
92.1 M1TNRmFxd3C2b4Ppd{BCe3OjeR?= NUnXXY05PTByIH7N MX60PEBp M2fT[2ROW09? M4\yRolv\HWlZYOgZZBweHSxc3nz M4fhWVI3Ozl5MkKz
Omm1.3 NX\2OW9ySXCxcITvd4l{KEG|c3H5 M1zyfFUxOCCwTR?= NWLzVGlKPDhiaB?= MYPEUXNQ NEeyNHNqdmS3Y3XzJIFxd3C2b4Ppdy=> Mnv5NlY{QTd{MkO=
92.1 MmexR4VtdCCFeXPs[UBCe3OjeR?= NETBNnU2ODBibl2= MUiyOE81QC95MjDo M3j0VmROW09? Ml3YbY5lfWOnczD0bIUh[2WubDDhZ4N2dXWuYYTpc44h[XRic4XiMWcyyqB? Mn\PNlY{QTd{MkO=
Omm1.3 NY\VTFBQS2WubDDDfYNt\SCDc4PhfS=> NXnVSWE4PTByIH7N NELDcFUzPC92OD:3NkBp MXfEUXNQ Ml3HbY5lfWOnczD0bIUh[2WubDDhZ4N2dXWuYYTpc44h[XRic4XiMWcyyqB? MnXmNlY{QTd{MkO=
A549 M37WdmZ2dmO2aX;uJGF{e2G7 M3zkNlExOC92MECvNVAxOCCwTR?= MUGyOEBp MkjueZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>? NInZN3kzPjJzMkG5PS=>
MCF-7 NWeydW5HTnWwY4Tpc44hSXO|YYm= MnLSNVAxNzRyMD:xNFAxKG6P M2[4fFI1KGh? MorOeZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>? NXvjRWE3OjZ{MUKxPVk>
HEK293 M2fKfGZ2dmO2aX;uJGF{e2G7 NX3yd2ppOTByL{SwNE8yODByIH7N M335VFI1KGh? NWDC[m4{fXC{ZXf1cIF1\XNiYX7kJIFkfGm4YYTld{BUUVKWMR?= M3LZSVI3OjF{MUm5
858 NV\PNopCS2WubDDWbYFjcWyrdImgRZN{[Xl? Mnm3NE0yKM7:TR?= NH3We4g2KGR? NY[yW2NwTE2VTx?= M3fx[4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1HhUVI3OjB4M{Oz
DDR2L63V NYS5XmlxS2WubDDWbYFjcWyrdImgRZN{[Xl? NFq4OWYxNTFizszN NHzySpQ2KGR? MoPQSG1UVw>? NU\xR|BV\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MkLxNlYzODZ|M{O=
BE(2)-C M2mxWGNmdGxiVnnhZoltcXS7IFHzd4F6 MlLnNUDPxE1? M{KxTVEuPCCm M1OxZoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 Ml7UNlYxPjd2NkS=
IMR-32 MXLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NX7VdowzOSEQvF2= MVqxMVQh\A>? NE\TdJRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? M2PyNVI3ODZ5NE[0
JF MkTIR4VtdCCYaXHibYxqfHliQYPzZZk> MmDYNUDPxE1? NInqdVgyNTRiZB?= NVHPcI9T\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? NF\FS5gzPjB4N{S2OC=>
BE(2)-M17 MVTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MYWxJO69VQ>? MlLkNU01KGR? M3KzcIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 M2\TPFI3ODZ5NE[0
SK-N-SH MlvrR4VtdCCYaXHibYxqfHliQYPzZZk> NFu0UYUyKM7:TR?= NVH5eWtOOS12IHS= M3LQNYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 MmH2NlYxPjd2NkS=
SK-N-DZ  NHXsUJRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MoTFNUDPxE1? MmjRNU01KGR? MlLr[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> MmXDNlYxPjd2NkS=
HMC-1.1  MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEn0[mo2NTVyMECgcm0> MkC4OFghcA>? NH22[HFFVVOR NV;SO5dYcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M{GxcFI3ODV3M{Cz
HMC-1.2 NXPSVG5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWK1MVUxODBibl2= M17JbVQ5KGh? MXvEUXNQ NWXlbYpMcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NIHyVWMzPjB3NUOwNy=>
ROSA KIT WT  M{jiZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmflOU02ODByIH7N MnjDOFghcA>? MmrJSG1UVw>? M1zWd4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NXTxT3RsOjZyNUWzNFM>
ROSA KIT D816V NGjXO3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXy1MVUxODBibl2= NWPtfFY4PDhiaB?= MnjjSG1UVw>? MorObY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NWD1SJpCOjZyNUWzNFM>
HMC-1.1  M17EfGFxd3C2b4Ppd{BCe3OjeR?= MYGyNFAuPTByMDDuUS=> NHH0Vo01QCCq MlOySG1UVw>? NFXv[4NqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NH62SlczPjB3NUOwNy=>
HMC-1.2 MoDGRZBweHSxc3nzJGF{e2G7 MWmyNFAuPTByMDDuUS=> NGHUO201QCCq MmnkSG1UVw>? M13GPIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVHqXXR[OjZyNUWzNFM>
ROSA KIT WT  M4n4b2Fxd3C2b4Ppd{BCe3OjeR?= M2PoblIxOC13MECwJI5O Ml;6OFghcA>? MYnEUXNQ MlPlbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M4LV[lI3ODV3M{Cz
ROSA KIT D816V MljpRZBweHSxc3nzJGF{e2G7 NHq2ToIzODBvNUCwNEBvVQ>? M4\F[|Q5KGh? NVWyc|VZTE2VTx?= M1;KcYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYGyOlA2PTNyMx?=
494H MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVyzbnkzPzJiaB?= MlO4SG1UVw>? MW\JR|UxRTBwMUKyxtExNjByNDFOwG0> MUCyOVk1PDV4Nh?=
493H MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU[3NkBp NY\xTm55TE2VTx?= MkK3TWM2OD1yLkC0O:KyOC5yMEmg{txO MYWyOVk1PDV4Nh?=
716H NGTY[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnnO|IhcA>? NEHoSXNFVVOR M{O5V2lEPTB;MD6yNVLDuTBwMEO0JO69VQ>? NH3VVoszPTl2NEW2Oi=>
148I MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPn[pFCPzJiaB?= Ml;JSG1UVw>? NW\TNZNwUUN3ME2wMlI5PMLzMD6wN|Uh|ryP MXKyOVk1PDV4Nh?=
98Sc MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLJO|IhcA>? Mn\3SG1UVw>? NFPXTVhKSzVyPUCuNVE2yrFyLkCwOEDPxE1? MXuyOVk1PDV4Nh?=
89R NIr2W2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYW3NkBp M3jaTGROW09? NETGU|ZKSzVyPUCuNVI3yrFyLkCwN{DPxE1? MYmyOVk1PDV4Nh?=
494L NHPU[HBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPJXIg4OiCq NXXMbFRQTE2VTx?= MVnJR|UxRTBwM{G3xtExNjBzMjFOwG0> MmfUNlU6PDR3Nk[=
493L NGPw[lhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGK0[ZU4OiCq MoXRSG1UVw>? MoC4TWM2OD1yLkC1NOKyOC5yMUGg{txO MnnNNlU6PDR3Nk[=
148L M3TQbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnUWHg4OiCq MUDEUXNQ NX\vRVl[UUN3ME2wMlE1PsLzMD6wNVch|ryP NV3GN2xQOjV7NES1OlY>
98L MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlftO|IhcA>? MWTEUXNQ NVHlNmg{UUN3ME2wMlMxQcLzMD6wNlkh|ryP NHPyZngzPTl2NEW2Oi=>
OS17 NVXT[Vc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPJcmJ[PzJiaB?= MUPEUXNQ NXjndWZxUUN3ME2wMlA4QcLzMD6wNFMh|ryP NELpUFAzPTl2NEW2Oi=>
OS9 NYfoenFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zVPVczKGh? M4rHUWROW09? NXLDXo46UUN3ME2wMlQxPsLzMD6wNlgh|ryP NUL1ZYhtOjV7NES1OlY>
MG63 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYm3NkBp NX\FNm1STE2VTx?= NX;We2NsUUN3ME2wMlEyPMLzMD6wNlUh|ryP MmPRNlU6PDR3Nk[=
SAOS2 MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7RO|IhcA>? MkPjSG1UVw>? MWHJR|UxRTBwMkG3xtExNjByMzFOwG0> NV3GfJpwOjV7NES1OlY>
U2OS M{mzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELzcWg4OiCq M2O1eGROW09? MWfJR|UxRTBwMUm4xtExNjByODFOwG0> NX\IXXpKOjV7NES1OlY>
SJSA-1 NFrlbXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX23NkBp MVHEUXNQ NFXoW4JKSzVyPUCuNVAxyrFyLkCxNEDPxE1? M4HNXVI2QTR2NU[2
494H M4XmemFxd3C2b4Ppd{BCe3OjeR?= NHqyeooxNjJ3L{CuOU8yNjBizszN MoXPNlQhcA>? MoLPSG1UVw>? Ml\3bY5kemWjc3XzJIxmfmWuczDv[kBkdGWjdnXkJINie3Cjc3WtN:Kh M1HKU|I2QTR2NU[2
148I MlvVRZBweHSxc3nzJGF{e2G7 NF;oeZIxNjJ3L{CuOU8yNjBizszN NYC5cmFZOjRiaB?= MWLEUXNQ M{\tNIlv[3KnYYPld{Bt\X[nbIOgc4Yh[2ynYY\l[EBk[XOyYYPlMVPDqA>? Mo\2NlU6PDR3Nk[=
OS17 MYnBdI9xfG:|aYOgRZN{[Xl? NGjyXHkxNjJ3L{CuOU8yNjBizszN MVeyOEBp NWLw[HBiTE2VTx?= MXTpcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> NWjZUXg{OjV7NES1OlY>
494H M4f6OmFxd3C2b4Ppd{BCe3OjeR?= MoTtNgKBkc7:TR?= MlG3OFghcA>? NFzYNGFFVVOR NYXjO5hQcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 MoexNlU6PDR3Nk[=
148I NXTMWVc4SXCxcITvd4l{KEG|c3H5 M{PXflHjiIoQvF2= MoqzOFghcA>? M1fYTWROW09? MmLobY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 MXqyOVk1PDV4Nh?=
OS17 NGnpbWpCeG:ydH;zbZMhSXO|YYm= NYnLZnF5OeLCid88US=> M4\seFQ5KGh? MUHEUXNQ MX3pcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bIm= NUn6TGY5OjV7NES1OlY>
MOLM13 M{fM[mFxd3C2b4Ppd{BCe3OjeR?= MojxNlUxKG6P NYrhWGhYPDhiaB?= NHXY[HpFVVOR NILL[|FqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicYXpfoFzfGmwaXK= M4Lh[|I2ODV|OEK1
MV4-11  NVv6d3BbSXCxcITvd4l{KEG|c3H5 NITvVpkzPTBibl2= MnfQOFghcA>? M4HCeGROW09? NIW3RYJqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicYXpfoFzfGmwaXK= MlHSNlUxPTN6MkW=
MOLM13 NYXQWWNLTnWwY4Tpc44hSXO|YYm= MmO4NlUxKG6P NYXnfXFVOjRiaB?= NFzoTnFFVVOR NF3LPZRmdmijbnPld{ByfWm8YYL0bY5q[i2rbnT1Z4VlKG2xcnWgdFIyNCCESV2sJIFv\CClbHXheoVlKFCDUmC= NVq1fYlWOjVyNUO4NlU>
MV4-11  MYrGeY5kfGmxbjDBd5NigQ>? M2C1SVI2OCCwTR?= MUKyOEBp MWnEUXNQ NGLBVJRmdmijbnPld{ByfWm8YYL0bY5q[i2rbnT1Z4VlKG2xcnWgdFIyNCCESV2sJIFv\CClbHXheoVlKFCDUmC= M4TsWlI2ODV|OEK1
MOLM13 MY\BdI9xfG:|aYOgRZN{[Xl? NEeyNJUzPTBibl2= NEOx[GQ1QCCq MXzEUXNQ MnvvbY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHCxbnH0bY5q[g>? NH2wR|gzPTB3M{iyOS=>
MV4-11  MkK1RZBweHSxc3nzJGF{e2G7 M{TYelI2OCCwTR?= NVvzd4dDPDhiaB?= MXrEUXNQ NYP0O|dTcW6mdXPld{B{cWewaX\pZ4FvfGy7IHHwc5B1d3OrczDjc5Rz\WG2bXXueEB4cXSqIIDvcoF1cW6rYh?= Ml;5NlUxPTN6MkW=
Hela NVrlUGFlS2WubDDWbYFjcWyrdImgRZN{[Xl? NWK0dYZsOC13MECgcm0> M2LmVVczKGh? MVnEUXNQ MXzk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NHO5U|czPTByOUK5OS=>
HBL-1 MoTDR4VtdCCYaXHibYxqfHliQYPzZZk> MnrkNE02ODBibl2= MVu3NkBp MXTEUXNQ M1G4XYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MmjDNlUxODl{OUW=
HLY-1 MoL0R4VtdCCYaXHibYxqfHliQYPzZZk> MojENE02ODBibl2= MnLXO|IhcA>? NHe5W|RFVVOR M4\BdYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M2X6OVI2ODB7Mkm1
OCI-Ly3 MYjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{fYdlAuPTByIH7N MXe3NkBp MWrEUXNQ M{O2UIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NVTyb45HOjVyMEmyPVU>
OCI-Ly10 NUKwXlM6S2WubDDWbYFjcWyrdImgRZN{[Xl? Mli5NE02ODBibl2= M4iwblczKGh? MkezSG1UVw>? Morq[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MWSyOVAxQTJ7NR?=
SU-DHL-4 NXPKU4g6S2WubDDWbYFjcWyrdImgRZN{[Xl? Mn3XNE02ODBibl2= NYXkRVE5PzJiaB?= Mof2SG1UVw>? MXjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mn;ONlUxODl{OUW=
SU-DHL-5 NITtb|hE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{\tZlAuPTByIH7N NHTuOms4OiCq MXvEUXNQ M1KwcYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWn5bnEyOjVyMEmyPVU>
SU-DHL-6 NV;ITnJwS2WubDDWbYFjcWyrdImgRZN{[Xl? NULaNIdxOC13MECgcm0> NF;veoI4OiCq NG[yWm5FVVOR Mmrr[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NWXLb|I{OjVyMEmyPVU>
SU-DHL-10 MkHxR4VtdCCYaXHibYxqfHliQYPzZZk> Mn\mNE02ODBibl2= MX:3NkBp MWnEUXNQ M2HKcIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Ml7SNlUxODl{OUW=
RC-K8 NYTVSpdvS2WubDDWbYFjcWyrdImgRZN{[Xl? NH;KeVAxNTVyMDDuUS=> NV7sTW02PzJiaB?= M4rKc2ROW09? NVfjeWx3\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MorCNlUxODl{OUW=
OCI-Ly8 NWjOWYh{S2WubDDWbYFjcWyrdImgRZN{[Xl? MkPBNE02ODBibl2= MlrqO|IhcA>? M{XDbmROW09? NXPXPGhI\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MVmyOVAxQTJ7NR?=
OCL-Ly18 M4nRTGNmdGxiVnnhZoltcXS7IFHzd4F6 M{W1NFAuPTByIH7N NHfRNnc4OiCq M3fTbmROW09? NV7UboRP\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MlziNlUxODl{OUW=
OCI-Ly3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTGNVczNzJ3MD:1NFAhdk1? MX[yM|ch\A>? Mo\2SG1UVw>? MkXvbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?= Ml[xNlUxODl{OUW=
OCI-Ly8 M2TVe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV:xO|IwOjVyL{WwNEBvVQ>? MV:yM|ch\A>? M3vxO2ROW09? M2Lj[4lv\HWlZYOgZ4VtdC2leXPs[UBienKnc4SgZZQhe3WkLVexJJdqfGhibXnubY1idCClZXzsJIRm[XSqwrC= M2XMe|I2ODB7Mkm1
SU-DHL-4 M4TXWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1job|E4Oi9{NUCvOVAxKG6P NWnvUlJ1Oi95IHS= NEjCXmFFVVOR NWfFSoRmcW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC|dXKtS|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=> NXLRTGlJOjVyMEmyPVU>
SU-DHL-10 NGDO[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIP1UJMyPzJxMkWwM|UxOCCwTR?= MUWyM|ch\A>? Mm\sSG1UVw>? MULpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2IHH0JJN2[i2JMTD3bZRpKG2rbnntZYwh[2WubDDk[YF1cMLi NHTGbZEzPTByOUK5OS=>
OCI-Ly3 MVHBdI9xfG:|aYOgRZN{[Xl? MVGxO|IwOjVyIH7N MnXjO4Q> MmfLSG1UVw>? MkfnbY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 MW[yOVAxQTJ7NR?=
OCI-Ly8 Ml73RZBweHSxc3nzJGF{e2G7 NY\JVXRbOTd{L{K1NEBvVQ>? MlfZO4Q> NH6wdlZFVVOR MnvjbY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 NWTE[lZpOjVyMEmyPVU>
SU-DHL-4 NFLRWJdCeG:ydH;zbZMhSXO|YYm= NUjpZWkyOTd{L{K1NEBvVQ>? M1TV[|dl NUfNV4pKTE2VTx?= MWfpcoNz\WG|ZYOgZ4F{eGG|ZT2zM|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm= NEDTOZgzPTByOUK5OS=>
SU-DHL-10 NVfORZZiSXCxcITvd4l{KEG|c3H5 M4jPfFE4Oi9{NUCgcm0> NFvtR3Q4\A>? MVrEUXNQ NF;vUYlqdmO{ZXHz[ZMh[2G|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk> MoDGNlUxODl{OUW=

... Click to View More Cell Line Experimental Data

In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Mice bearing NMC 797 xenografts
  • Formulation: 5% DMSO in 5% dextrose
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S

CAS No. 1268524-70-4
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can I reconstitute the compound for in vivo injection?

  • Answer:

    JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID